The Automated Daily - Top News Edition

The Automated Daily
  • 0.0 (0)
  • Daily News
  • Updated Daily

Welcome to 'The Automated Daily - Top News Edition', your ultimate source for a streamlined and insightful daily news experience.

  1. Government stakes in AI firms & US military accelerates AI adoption - News (Jun 8, 2026)

    8h ago

    Government stakes in AI firms & US military accelerates AI adoption - News (Jun 8, 2026)

    Please support this podcast by checking out our sponsors: - Invest Like the Pros with StockMVP - https://www.stock-mvp.com/?via=ron - Discover the Future of AI Audio with ElevenLabs - https://try.elevenlabs.io/tad - Prezi: Create AI presentations fast - https://try.prezi.com/automated_daily Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily Today's topics: Government stakes in AI firms - A rare political crossover is emerging as Donald Trump and Bernie Sanders both float ideas for the public to share in AI profits, including talk of public ownership stakes and wealth funds. Keywords: public stake, AI companies, jobs, national security, wealth fund. US military accelerates AI adoption - A new US National Security Presidential Memorandum orders faster adoption of advanced AI across defense agencies, with new limits around censorship and unlawful domestic surveillance. Keywords: Pentagon, AI models, autonomous weapons, procurement, guardrails. Israel–Iran strikes shake markets - Israel launched fresh airstrikes on Iran, met by Iranian missile fire, reviving regional escalation fears and pushing oil higher while equities slipped. Keywords: airstrikes, ballistic missiles, Brent crude, regional conflict, market volatility. Nuclear arms rollback concerns - SIPRI’s Yearbook 2026 warns the long decline in global nuclear warheads may be ending as modernization accelerates, transparency falls, and New START has expired. Keywords: SIPRI, nuclear modernization, New START, high alert, arms control. New weekly diabetes drug results - Phase 3 data suggests the experimental weekly injection retatrutide significantly lowers HbA1c and drives notable weight loss in adults with type 2 diabetes, though longer-term comparisons are still needed. Keywords: retatrutide, HbA1c, weight loss, trial results, side effects. Twice-yearly HIV prevention rollout - Gauteng is starting a rollout of lenacapavir, a twice-yearly HIV prevention injection aimed at people at high risk, supporting South Africa’s 2030 goals. Keywords: lenacapavir, HIV prevention, Gauteng, long-acting injection, public health. UK push for child safety controls - UK Prime Minister Keir Starmer is pressuring tech companies to add device-level tools to curb nude image sharing by children, with legislation threatened if firms don’t move quickly. Keywords: child safety, device-level controls, sextortion, age checks, regulation. Chip memory supply for AI - NVIDIA and SK hynix are teaming up long-term to secure next-generation memory for AI systems, reflecting how hardware supply constraints are shaping the pace of AI buildouts. Keywords: AI infrastructure, memory bottleneck, semiconductor supply, partnership, capacity. Episode Transcript Government stakes in AI firms Let’s start with artificial intelligence—because the conversation is shifting from “who builds it” to “who benefits from it.” In the US, officials and politicians are increasingly debating whether the public should hold an ownership stake in major AI companies. The argument is straightforward: if AI is going to reshape jobs, productivity, and national security, the upside shouldn’t flow only to private shareholders. OpenAI CEO Sam Altman has reportedly discussed the concept with Senator Bernie Sanders, whose camp has floated a major public stake to fund a public wealth fund—though support for the exact number is far from settled. What’s notable is that President Donald Trump has also talked about Americans becoming “partners” in the AI boom, and is expected to convene top AI leaders at the White House. Abroad, similar instincts are showing up in different forms—like Europe pushing to reduce dependence on US cloud giants for sensitive government work, and the UK setting up a sovereign AI investment fund. No deal is close. But the fact that “public ownership” is now part of the mainstream AI debate signals a turning point: governments are preparing to treat AI less like a typical tech sector—and more like critical infrastructure. US military accelerates AI adoption At the same time, the US is moving to speed AI adoption inside the military. President Trump has signed a National Security Presidential Memorandum directing defense agencies to accelerate the use of advanced AI across missions, and to pull in leading models from multiple vendors rather than relying on a single provider. There are also two political signals baked into the order. One: the Pentagon is being told to update its approach to autonomous weapon systems—an area that’s been debated for years, but is now being pushed toward clearer rules. Two: the memo includes boundaries meant to address public concerns, including language against building defense AI designed to censor speech, embed ideological bias, or enable unlawful surveillance of Americans. Another line stands out for industry: it bars companies from disabling or materially altering AI systems used by US warfighters without government approval. In plain English, once a system is in the field, Washington wants to ensure it can’t be remotely “switched off” by a vendor decision. Israel–Iran strikes shake markets Now to the Middle East, where a fragile pause has been shaken. Israel carried out new airstrikes on Iran—described as the first direct exchange since an April ceasefire that paused a US–Israel war with Iran. Iranian state media reported explosions in multiple cities, including Tehran and Isfahan. Iran then responded by firing around ten ballistic missiles toward northern Israel, after Israel also bombed a target in southern Beirut. President Trump publicly urged both sides to stop shooting, a comment that also highlights the tension between Washington’s stated posture and Israel’s on-the-ground decisions. The ripple effects were immediate across the region: Saudi Arabia reportedly sounded missile-alert sirens near an airbase that hosts US forces, and Israel said it worked to intercept a missile launched from Yemen, where the Houthis have been involved in the broader conflict. Markets reacted fast, too. Oil jumped, with Brent crude rising by several dollars to the mid‑90s per barrel range, and Asian stocks slid. The takeaway is familiar but important: even a limited exchange can quickly raise global economic anxiety, because energy prices and shipping risk can move on headlines alone. Nuclear arms rollback concerns Staying with security—one of the most sobering reads today comes from SIPRI’s Yearbook 2026. The Stockholm International Peace Research Institute warns that nuclear-armed states are increasingly treating nuclear weapons as instruments of national power again—reversing decades of efforts to reduce their role. SIPRI estimates the world had a little over twelve thousand nuclear warheads as of January 2026, with thousands in military stockpiles and roughly four thousand deployed. A significant share of deployed warheads remain on high operational alert, mostly in Russia and the United States. The big shift is trendline and trust. SIPRI expects the long-running decline in total warhead numbers to end, as dismantlement slows and new deployments accelerate. That warning lands as New START—the last major US–Russia nuclear arms control agreement—expired in February 2026. Add reduced transparency, weaker crisis-management channels, and rising geopolitical tension, and you get a higher risk of miscalculation. The report also points to China as the fastest-growing arsenal, while noting the US and Russia still hold the vast majority of stockpiled warheads—and both are modernizing under intense strategic competition. In Europe, SIPRI flags renewed debate about a bigger nuclear role in security planning, including interest in broader nuclear-sharing arrangements, alongside claims of Russian nuclear deployments in Belarus. And politically, the non-proliferation system looks shakier after the 2026 NPT Review Conference again failed to produce an outcome document—raising questions about how much cooperation remains in the tank. New weekly diabetes drug results On health news, there’s a potentially significant development for type 2 diabetes. Phase 3 trial results suggest an experimental weekly injection called retatrutide can both lower blood sugar and reduce body weight—two outcomes that are often linked, but not always easy to achieve together. In a forty-week study of adults not already on diabetes medication, average long-term blood sugar, measured by HbA1c, fell substantially more with retatrutide than with placebo. Participants also saw sizable average weight loss, alongside improvements in markers like cholesterol and blood pressure. Experts describe the results as encouraging—possibly life-changing for some patients—but there are important caveats. We still need longer-term data, and there wasn’t a direct head-to-head comparison here against some of today’s leading drugs. And like other medicines in this space, side effects were mainly gastrointestinal, with a small number of serious adverse events reported across the study groups. The story to watch next is how it performs over time, in real-world care, and against established options. Twice-yearly HIV prevention rollout Also in public health, South Africa is expanding prevention tools against HIV. Gauteng’s Department of Health says it will begin rolling out lenacapavir on Monday as a long-acting prevention injection. The key practical difference: it’s given only twice a year, aimed at HIV-negative people at high risk of infection. The first phase is planned across more than a hundred facilities, with tens of thousands of people expected to receive the injection by early next year. Officials say supplies will be delivered regularly to avoid interruptions. Why it’s interesting is not just the medicine, but the strategy: offering choices. Long-acting prevention can help people who struggle with da

    10 min
  2. Base editing in human embryos & AI-designed universal coronavirus vaccine - News (Jun 7, 2026)

    22h ago

    Base editing in human embryos & AI-designed universal coronavirus vaccine - News (Jun 7, 2026)

    Please support this podcast by checking out our sponsors: - Invest Like the Pros with StockMVP - https://www.stock-mvp.com/?via=ron - Prezi: Create AI presentations fast - https://try.prezi.com/automated_daily - Effortless AI design for presentations, websites, and more with Gamma - https://try.gamma.app/tad Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily Today's topics: Base editing in human embryos - A Columbia University team reported base editing in early human embryos in a bioRxiv preprint, reviving safety and ethics debates after the CRISPR-baby scandal. Keywords: base editing, embryos, mosaicism, ethics, CRISPR. AI-designed universal coronavirus vaccine - Cambridge researchers say an AI-designed “universal sarbecovirus” vaccine looked safe in a small Phase 1 trial, aiming for broad protection across SARS-like viruses. Keywords: AI vaccine design, sarbecovirus, Phase 1, variants, preparedness. New weight-loss shot for diabetes - Phase 3 results suggest retatrutide, a weekly triple-action injection, lowered HbA1c and weight in type 2 diabetes, though longer-term comparisons are still needed. Keywords: retatrutide, type 2 diabetes, HbA1c, weight loss, GLP-1. Twice-yearly HIV prevention injection - South Africa’s Gauteng province is rolling out lenacapavir, a twice-yearly HIV prevention shot, focusing on high-risk groups to support the 2030 AIDS goals. Keywords: lenacapavir, PrEP, long-acting injection, Gauteng, HIV prevention. Robots vs reality in China - China’s humanoid robots are getting flashier and drawing orders, but analysts say real-world usefulness still lags and commercialization remains limited. Keywords: humanoid robots, China, robotics demand, logistics, bubble risk. US military AI acceleration memo - President Trump signed a national security memo pushing faster adoption of advanced AI across US defense agencies, including new attention to autonomous weapons policy. Keywords: Pentagon AI, national security memorandum, autonomous weapons, vendors, governance. Public stake idea for AI firms - The White House has discussed ways for the public to share in AI-company gains, including a reported concept of an equity stake in OpenAI tied to a Public Wealth Fund. Keywords: OpenAI stake, public wealth fund, AI policy, government ownership, equity. Australia’s AI data-center power crunch - Australia’s data-center boom is powering construction growth but raising concerns about electricity demand, price pressure, and how much long-term value stays onshore. Keywords: Australia data centers, AI boom, AEMO, power demand, wholesale prices. US-Iran talks on ending war - Trump says the US and Iran are close to an agreement to end a three-month conflict, but uranium removal and verification details remain the crucial sticking points. Keywords: US-Iran deal, enriched uranium, verification, troops, ceasefire talks. NASA’s quiet-supersonic X-59 milestone - NASA’s X-59 achieved its first supersonic flight, advancing a program designed to reduce sonic booms and potentially reopen overland supersonic travel. Keywords: NASA X-59, Quesst, supersonic, sonic boom, regulations. Episode Transcript Base editing in human embryos We’ll start with the headline that’s raising eyebrows in both science and ethics circles. A research team led by Dieter Egli at Columbia University has posted a preprint describing what appears to be the first use of “base editing” in early-stage human embryos. Unlike older approaches that cut DNA, base editing aims for more precise, single-letter changes—on paper, a safer direction. But the results still show major hurdles: edits often appeared in some cells but not others, and at higher doses the process could even stop embryos from dividing. The bigger story here is what this unlocks—and what it tempts. Supporters see a path toward mimicking naturally protective mutations tied to lower heart-disease risk or reduced severity in blood disorders like sickle cell disease. Critics warn it could make “embryo improvement” feel more reachable than it should, especially given how widely IVF and genetic testing are already available. For now, the message from the data is clear: the science is advancing, but it’s far from clinic-ready. AI-designed universal coronavirus vaccine Staying with health—and shifting from controversy to preparedness—researchers at the University of Cambridge and their spin-out, DIOSynVax, say they’ve completed an early human trial of a vaccine antigen designed entirely with computer simulations and machine learning. In a small Phase 1 study of healthy volunteers, the team reports no significant side effects. The ambition is the striking part: instead of building a vaccine around one known virus, they designed an antigen meant to represent shared features across the broader “sarbecovirus” family—the group that includes SARS-CoV-1 and SARS-CoV-2. If later trials show strong protection, it could mean fewer frantic updates every time a new variant appears, and faster vaccine design when a new relative of COVID shows up. New weight-loss shot for diabetes Another medical update with major real-world stakes: Phase 3 trial results suggest the experimental weekly injection retatrutide helped adults with type 2 diabetes significantly lower blood sugar and lose substantial weight over 40 weeks. Participants who weren’t already on diabetes medication saw meaningfully larger drops in HbA1c than placebo, and also lost far more body weight, alongside improvements in cholesterol and blood pressure. Researchers describe retatrutide as a “triple-action” drug, aiming to tackle appetite, glucose control, and energy use at the same time. Side effects were mostly in the familiar category for this class of drugs—mainly gastrointestinal—and experts are encouraged, while also pointing out what’s still missing: longer-term data and direct comparisons with established treatments like semaglutide or tirzepatide. Twice-yearly HIV prevention injection From treatment to prevention: South Africa’s Gauteng Department of Health is beginning a rollout of lenacapavir as a long-acting HIV prevention injection. It’s given twice a year and is aimed at HIV-negative people at higher risk of infection. The plan is to start across more than a hundred health facilities in the province, with a goal of reaching tens of thousands of people over the coming months. Public health officials are prioritizing groups that have often been underserved by prevention tools—especially adolescent girls and young women, sex workers, and others who face elevated risk. The significance is straightforward: adherence has long been one of the biggest barriers for HIV prevention, and a twice-yearly option could make staying protected much more realistic for many people. Robots vs reality in China Now to technology and the economy—and a reality check on humanoid robots. In China, robot makers are showing off increasingly agile humanoids, with companies claiming thousands of orders from governments and businesses. But analysts and investors are warning that demand still isn’t matching the scale of manufacturing ambition. A lot of these machines look impressive in controlled demos, yet struggle with messy, unpredictable environments—the places where a “general-purpose helper” would actually have to work. The near-term opportunity appears more practical: industrial sites and logistics, like warehouses, power plants, and data centers, where tasks are more structured and where a robot’s limits can be managed. The broader race is also taking shape geopolitically: the US is widely seen as stronger on advanced AI systems, while China’s edge is hardware supply chains, data, and mass production. Chinese regulators, notably, have even warned about bubble dynamics—big expectations, but limited real commercialization so far. US military AI acceleration memo On the US policy front, President Trump has signed a National Security Presidential Memorandum pushing faster adoption of advanced AI across defense agencies. The memo calls for rapid onboarding of top AI models from multiple vendors and for adapting commercial and open-source tools for military missions. It also signals more formal attention to autonomous weapons policy, directing the Defense Department to update guidance on how those systems are governed. One notable clause says companies shouldn’t be able to disable or modify AI used by US warfighters without government approval—an attempt to prevent critical tools from being turned off in a crisis. The memo also includes language aiming to limit certain domestic risks, saying defense agencies shouldn’t create or release AI designed to censor free speech, embed ideological bias, or enable unlawful surveillance of Americans. The big picture: Washington is trying to move quickly on military AI while also drawing some red lines—though how those lines hold up in practice is the real test. Public stake idea for AI firms And there’s another AI-related idea circulating that could reshape how the public relates to the industry. Trump says he’s been talking with AI companies about arrangements that would let “the American people” benefit directly from AI’s success. Reporting suggests discussions have included the federal government taking an equity stake in OpenAI, potentially routing proceeds into a proposed “Public Wealth Fund.” Supporters frame it as the public getting a stake in a transformational technology. Critics see risks: deeper government-corporate entanglement, and the possibility that ownership becomes a backdoor route to bailouts or political influence. It’s also notable that a similar concept is appearing from the political left, with proposals for AI companies to pay a tax in shares. Regardless of ideology, the underlying question is the same: if AI creates enormous private value, should the pu

    10 min
  3. Embryo base editing milestone & AI-designed universal coronavirus vaccine - News (Jun 6, 2026)

    2d ago

    Embryo base editing milestone & AI-designed universal coronavirus vaccine - News (Jun 6, 2026)

    Please support this podcast by checking out our sponsors: - Discover the Future of AI Audio with ElevenLabs - https://try.elevenlabs.io/tad - Consensus: AI for Research. Get a free month - https://get.consensus.app/automated_daily - KrispCall: Agentic Cloud Telephony - https://try.krispcall.com/tad Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily Today's topics: Embryo base editing milestone - Scientists reported the first use of base editing in early-stage human embryos, a more precise CRISPR-style method, raising fresh safety and ethics concerns around mosaicism and enhancement. AI-designed universal coronavirus vaccine - A Cambridge team says an AI-designed coronavirus “super-antigen” has been tested in humans, aiming for broad protection across coronaviruses and future spillovers—early results were modest but promising. Long-acting HIV prevention rollout - South Africa began rolling out lenacapavir, a twice-yearly PrEP injection that could boost HIV prevention by solving daily-pill adherence issues, but access is constrained by funding cuts and limited supply. New KRAS pancreatic cancer drug - Phase 3 results for daraxonrasib showed markedly longer survival in KRAS-driven metastatic pancreatic cancer, potentially reshaping treatment for a historically hard-to-treat disease if regulators approve it. China’s humanoid robot reality check - China’s humanoid robot makers claim thousands of orders and show off agile machines, but analysts warn real-world usefulness still lags behind production ambitions due to cost, fragility, and messy environments. Canada’s AI sovereignty strategy - Canada unveiled a decade-long AI strategy focused on adoption, AI literacy, and “AI sovereignty,” including plans for domestic compute capacity and support to keep talent and companies at home. Self-improving AI and research race - From Anthropic’s AI-written code to Japan-U.S. autonomous labs, the competitive edge is shifting toward controlled feedback loops where AI helps improve products and speed up science—without fully autonomous self-upgrades. Episode Transcript Embryo base editing milestone We’ll start with that embryo-editing headline. Researchers led by Dieter Egli at Columbia University reported what they describe as the first use of “base editing” to change single DNA letters in early-stage human embryos. This was shared as a bioRxiv preprint, meaning it hasn’t been peer reviewed yet. Supporters say this matters because base editing can avoid the kind of double-strand DNA cuts that made earlier embryo experiments look especially risky. But the study also underlines how far this is from clinical reality: many embryos ended up “mosaic,” with edits in some cells but not others, and higher doses of the editor delivery appeared to stall cell division. The bigger reason this is back in the spotlight is ethical, not technical. After the 2018 CRISPR-baby scandal, researchers and regulators have tried to draw bright lines. Critics worry that relatively accessible IVF and genetic testing could tempt reckless attempts at so-called improvement—long before safety is there. Others argue that for many inherited diseases, existing embryo screening can already reduce risk without editing, which raises an uncomfortable question: does the first real demand end up being enhancement rather than therapy? AI-designed universal coronavirus vaccine Staying with health—this time, with a more hopeful story—South Africa has begun rolling out lenacapavir, a long-acting HIV prevention injection given just twice a year. The significance is simple: daily PrEP pills work well when taken consistently, but adherence is often the weak link, especially among adolescents and young women—groups that account for a large share of new infections. A twice-yearly shot could remove a huge practical barrier. The catch is access. The program is launching in hundreds of facilities in high-burden districts, but experts say the scale is limited by reduced prevention capacity after U.S. PEPFAR funding cuts, plus constrained supply and the lack of low-cost generics today. The Global Fund is financing enough doses for hundreds of thousands of people over two years—valuable, but still far from the kind of coverage that would rapidly bend national infection curves. The stakes are big: models suggest that with sustained, large-scale rollout over time, South Africa could push AIDS out of the “major public health problem” category. But that hinges on money, supply, and follow-through. Long-acting HIV prevention rollout Now to cancer treatment, where a single trial result can change the standard conversation. Researchers reported Phase 3 results for daraxonrasib, a targeted therapy for KRAS-driven metastatic pancreatic cancer. KRAS mutations are behind the vast majority of pancreatic tumors, and for years KRAS was treated like a near-impossible drug target. In this 500-patient trial for previously treated metastatic disease, overall survival increased from about 6.7 months with standard chemotherapy to 13.2 months with daraxonrasib. That’s a striking jump in a cancer known for grim outcomes. Side effects were common—things like rash, mouth sores, and gastrointestinal problems—but fewer people stopped treatment than with chemotherapy, and patients reported better quality of life. The company plans to seek regulatory approval, and if that moves quickly, oncologists could soon have a new cornerstone drug—and a new platform for combination therapies aimed at delaying resistance. New KRAS pancreatic cancer drug Let’s pivot to AI meeting biology in a different way. Researchers at the University of Cambridge say they’ve tested in humans a vaccine concept whose key antigen was designed entirely by artificial intelligence. Instead of chasing the latest variant, the AI reportedly sifted genetic sequences from many coronaviruses gathered through surveillance and designed a kind of broad “super-antigen,” aiming to train immunity across the coronavirus family—including possible future spillovers from animals. In a small first trial of 39 people, the main focus was safety, and the immune response was described as modest. That’s not a victory lap—but it is a proof-of-concept moment: the idea that you might pre-build vaccine candidates for viral families before the next outbreak. A larger study is planned to better measure effectiveness, and the same approach is being explored for other threats, including flu and H5N1. China’s humanoid robot reality check From vaccines to the physics lab: researchers at Chalmers University of Technology say they’ve cut the time needed to design advanced optical components by building the laws of physics into a neural network. In plain terms, instead of forcing an AI to learn electromagnetism the hard way—by chewing through huge volumes of simulation data—they gave the model a built-in understanding of key physical constraints. The result: far less training data needed, fewer obvious errors, and a dramatic reduction in the time it takes to evaluate new designs. Why it matters is what it enables: thinner, lighter optical systems, and potentially better photonic structures for future technologies—where traditional simulation can be painfully slow and expensive. It’s a reminder that the most useful “AI breakthroughs” aren’t always about bigger models; sometimes they’re about smarter rules. Canada’s AI sovereignty strategy Now to robots—specifically China’s push for humanoids. Chinese manufacturers are showing increasingly agile humanoid machines that can pull stunts and handle basic service tasks, and some companies claim they already have thousands of orders from governments and businesses. But analysts and investors are throwing cold water on the hype: demand may still be trailing factory ambitions because many humanoids look more impressive on a demo stage than they do in messy, unpredictable real-world settings. Fragile parts, high costs, and the need for structured environments are still big barriers. The geopolitical angle is also clear. The U.S. and China dominate the field, with the U.S. often viewed as stronger in the AI “brains,” while China leads in hardware supply chains, data collection at scale, and mass production capacity—plus strong policy support. In the near term, the most realistic growth is expected in controlled industrial settings like warehouses, power plants, and data centers, long before most people have a reliable household helper. Self-improving AI and research race Let’s talk policy and power—AI power, specifically. Canada has unveiled a national AI strategy for the next decade, framed by Prime Minister Mark Carney as an inevitability Canada needs to shape rather than fear. The plan includes major spending aimed at AI literacy and adoption across business and government, and it puts a name on a growing theme: “AI sovereignty.” The goal is to reduce reliance on foreign providers by expanding domestic computing capacity, including a secure public supercomputer and support for large-scale data centers. Canada also wants to keep talent from leaving—through research funding, university chairs, and faster immigration pathways for skilled workers—plus funding to invest in Canadian AI companies. One point drawing criticism: the strategy talks a lot about trust and safety concerns, but offers fewer concrete details on new safety rules than some Canadians expected. Story 8 Finally, the AI industry itself is evolving in a way that’s less sci-fi—and more operational. Companies are building feedback loops where AI helps create the next iteration of software and even AI itself. Anthropic says its models now write the majority of code merged into its codebase, shifting human engineers toward oversight, review, and deciding what “good” looks like. Microsoft is pushing a controlled

    9 min
  4. CAR-T clears path for transplants & AI-designed coronavirus vaccine tested - News (Jun 5, 2026)

    3d ago

    CAR-T clears path for transplants & AI-designed coronavirus vaccine tested - News (Jun 5, 2026)

    Please support this podcast by checking out our sponsors: - Invest Like the Pros with StockMVP - https://www.stock-mvp.com/?via=ron - Discover the Future of AI Audio with ElevenLabs - https://try.elevenlabs.io/tad - Consensus: AI for Research. Get a free month - https://get.consensus.app/automated_daily Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily Today's topics: CAR-T clears path for transplants - Engineered CAR-T cells helped highly sensitized kidney patients receive transplants by reducing antibody-driven rejection risk, potentially expanding access beyond dialysis. AI-designed coronavirus vaccine tested - Cambridge researchers tested an AI-designed “super-antigen” coronavirus vaccine concept in humans, aiming for broad protection against future variants and spillovers. GLP-1 drugs and cancer signals - ASCO-presented studies suggest GLP-1 medicines may correlate with lower cancer risk and improved outcomes, prompting calls for randomized clinical trials and careful safety review. Lenacapavir injection for HIV prevention - South Africa is rolling out twice-yearly Lenacapavir for HIV prevention, a long-acting PrEP option that could boost adherence and reduce new infections. EU pushes tech sovereignty laws - The European Commission proposed a Technological Sovereignty Package covering chips, cloud, AI, and open source to reduce dependence on non-EU suppliers and secure critical services. Canada’s AI plan and sovereignty - Canada’s national AI strategy includes billions for AI literacy, domestic computing capacity, and talent retention, while critics say safety and online protections are still vague. US–Japan AI research partnership - Japan and the US launched a $1 billion initiative to speed R&D using AI, including autonomous labs for quantum, fusion, and biotech, with an eye on strategic competition. Self-replicating AI worm raises alarms - University of Toronto researchers demonstrated a proof-of-concept self-replicating “AI worm” that adapts exploits using a local language model, highlighting new cyber defense needs. Google seeks sterile mosquito release - Google asked US regulators to allow large-scale releases of sterilized male mosquitoes carrying Wolbachia to reduce disease vectors, testing public acceptance of biological control. Largest cosmic magnetic field map - CSIRO and SKA Observatory partners released SPICE-RACS, the biggest magnetic-field map of the universe, enabling new studies of galaxy evolution and the cosmic web. Episode Transcript CAR-T clears path for transplants Let’s start with the medical story that could reshape organ transplantation for a very specific, very vulnerable group of patients. Two independent teams, writing in the New England Journal of Medicine, report that three people with end-stage kidney disease successfully received kidney transplants after a single treatment with engineered CAR-T immune cells. These patients were considered “highly sensitized,” meaning their immune systems carried high levels of antibodies that typically trigger rapid rejection—so high that compatible donors were effectively out of reach and dialysis was the only realistic option. More than a year later, the transplanted kidneys are still functioning, and the clinicians reported no notable side effects in these cases. The key idea is to use a patient’s own modified immune cells to dial down the specific antibody-producing cells that drive rejection risk. It’s early, and it’s only a few patients—but if larger studies confirm this, it could open transplant access for people who’ve been shut out by biology, not by a shortage of donors alone. AI-designed coronavirus vaccine tested Staying in health, researchers at the University of Cambridge say they’ve tested a fundamentally new vaccine concept in humans—one where the central antigen was designed entirely by artificial intelligence. Instead of aiming at one circulating strain, the AI looked across genetic sequences from many coronaviruses and designed a sort of “super-antigen” intended to train immunity across the whole family, including potential future animal-to-human spillovers. In a small early trial of 39 people, the focus was safety, and the immune response was described as modest. Still, the team argues the approach is promising enough to justify a bigger follow-up study of about 200 participants. The bigger idea here is preparedness: if vaccines can be designed to cover broader viral families, the world may not have to play catch-up as often when viruses mutate or jump species. GLP-1 drugs and cancer signals More provocative signals in medicine came out of the American Society of Clinical Oncology meeting, where researchers discussed a growing body of evidence around GLP-1 drugs—best known for diabetes and weight loss—and cancer outcomes. Across more than two dozen mostly observational studies using health records and real-world databases, GLP-1 users appeared to have lower risks for certain cancers and, in some analyses, better outcomes like reduced metastasis and improved survival. One large study in women linked GLP-1 use with a markedly lower breast cancer risk; another found lower odds of metastatic spread in several cancers. Researchers suspect the story could involve inflammation and metabolic effects, not just weight loss. But the caution is just as important: observational signals can be misleading, shaped by differences in who gets these medications and what care they can access. The takeaway is momentum—these patterns are consistent enough that experts are calling for randomized clinical trials to test whether GLP-1s can actually help prevent cancer or improve treatment results. Lenacapavir injection for HIV prevention And in HIV prevention, South Africa is marking a major milestone with the rollout of Lenacapavir, a long-acting injection designed to prevent infection with just two doses a year. President Cyril Ramaphosa is set to officially launch the programme in Secunda, alongside health leaders and international partners. The significance is practical: daily prevention pills work well, but adherence is hard in the real world. A twice-yearly option could widen access and make consistent protection more realistic for more people—especially in a country running the world’s largest HIV treatment programme, where preventing new infections remains essential to ultimately ending the epidemic. EU pushes tech sovereignty laws Now to policy and power: the European Commission has unveiled what it’s calling a European Technological Sovereignty Package, aimed at boosting Europe’s ability to build and control key digital technologies. The plan spans chips, artificial intelligence, cloud computing, and open source software, and it reflects a simple pressure point: rising AI-driven demand for computing, paired with heavy reliance on non-EU suppliers. The Commission’s argument is that reducing these dependencies isn’t just about industry—it’s about resilience for critical services like healthcare systems, energy grids, and digital public services. Whether the package delivers will depend on funding, execution, and how quickly Europe can translate ambition into capacity. Canada’s AI plan and sovereignty Canada is also pushing the idea of “AI sovereignty,” unveiling a national AI strategy for the next decade. Prime Minister Mark Carney framed AI adoption as inevitable and put more than two billion Canadian dollars on the table for AI literacy and faster uptake across business and government. Ottawa wants to build domestic computing muscle, including a secure public supercomputer and more Canadian data centres by 2030, while also trying to slow the talent drain with research funding, university positions, and faster immigration pathways for skilled workers. The plan emphasizes practical areas like healthcare, with money earmarked to cut administrative load and improve diagnostics. The political friction point: critics say the strategy is light on concrete details for AI safety and online protections—exactly the area where public anxiety is highest. US–Japan AI research partnership On the international stage, Japan and the United States announced a five-year, one-billion-dollar joint initiative to accelerate research using AI, with each country contributing half. Japan becomes the first international partner in the US “Genesis Mission” programme, and the collaboration is aimed at advanced fields like quantum technology, nuclear fusion, and biotechnology. A headline element is the push toward AI- and robotics-enabled labs—facilities that can run parts of the research process more continuously and systematically. Beyond the science, there’s geopolitics: officials framed it as a way to maintain a technological edge, with China clearly in the background of that conversation. Self-replicating AI worm raises alarms Now, a story that will make security teams sit up straighter. Researchers at the University of Toronto’s CleverHans Lab say they’ve built a proof-of-concept self-replicating “AI worm” that uses an open-weight language model to adapt as it moves through a network—rather than relying on a fixed, pre-planned playbook. In tests run in an isolated environment, the worm was able to identify vulnerabilities, gain higher levels of access, and spread widely. What’s especially unsettling is the economics: because the model can run locally on compromised machines, it may bypass the kinds of guardrails people associate with hosted AI services, and it can essentially use victims’ computing power to keep going. The researchers say they won’t publicly release the tool, and they’re urging defenses like tighter network segmentation and zero-trust approaches. The larger point is that AI isn’t only speeding up defenders—it can also compress the cost and time required for attackers. Google seeks sterile mos

    9 min
  5. Self-adapting AI worm cyber risk & Europe’s push for tech sovereignty - News (Jun 4, 2026)

    4d ago

    Self-adapting AI worm cyber risk & Europe’s push for tech sovereignty - News (Jun 4, 2026)

    Please support this podcast by checking out our sponsors: - Lindy is your ultimate AI assistant that proactively manages your inbox - https://try.lindy.ai/tad - KrispCall: Agentic Cloud Telephony - https://try.krispcall.com/tad - Prezi: Create AI presentations fast - https://try.prezi.com/automated_daily Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily Today's topics: Self-adapting AI worm cyber risk - University of Toronto researchers demonstrated a proof-of-concept “AI worm” using open-weight models that can adapt attacks in real time, raising new cybersecurity and critical-infrastructure concerns. Europe’s push for tech sovereignty - The European Commission unveiled a Technological Sovereignty Package, including Chips Act 2.0 and a Cloud and AI Development Act, aiming to reduce EU dependence on non-EU semiconductors, cloud, and AI suppliers. Google AI Overviews and publishers - The UK CMA will require Google to let publishers opt out of AI Overviews and to add clearer attribution, a move tied to traffic, content payments, and the future economics of online journalism. Math community’s AI warning - The Leiden Declaration on Artificial Intelligence and Mathematics warns that AI-generated but incorrect proofs, weak transparency, and corporate hype could pollute the research record and distort credit and incentives. Microsoft’s Majorana 2 quantum claim - Microsoft says its Majorana 2 quantum chip shows dramatically longer qubit stability, but limited public data and a lack of peer review are fueling calls for independent verification. Largest-ever cosmic magnetic field map - SPICE-RACS, built from ASKAP data, is the largest map yet of cosmic magnetic fields, using galaxy “rotation measures” to probe how magnetism shapes galaxy growth and the cosmic web. GLP-1 drugs and cancer signals - New ASCO-presented studies suggest GLP-1 drugs may correlate with lower cancer risk and better outcomes, but researchers stress observational limits and call for randomized clinical trials. Injectable microrobots for spinal repair - ETH Zurich researchers combined stem cells and magnetically responsive nanoparticles into injectable microrobots, helping severed spinal cord connections regrow in mice and improving movement outcomes. Sterile mosquito proposal in US - Google asked US regulators to allow releases of sterilized male mosquitoes in California and Florida, testing large-scale biological control for disease prevention and public acceptance. Kyrgyzstan wins UN Security Council seat - Kyrgyzstan was elected to the UN Security Council for 2027–2028, a rare diplomatic win for Central Asia that also revived calls for Security Council reform and broader regional representation. Episode Transcript Self-adapting AI worm cyber risk We’ll start with cybersecurity, because researchers at the University of Toronto are warning about a new category of threat: an “AI worm” that can adjust its approach as it moves through a network. In their proof-of-concept, the worm probes each machine, looks for known weaknesses, grabs credentials where it can, and then changes strategy on the next target—rather than behaving like the more predictable, scripted worms defenders are used to. The most unsettling twist is the economics: it can hijack infected machines to run the AI reasoning needed for future attacks, potentially making large-scale spread cheaper once it’s launched. The team says it removed details that would help criminals, but the message is clear—security plans built for yesterday’s malware may not hold up against attacks that can pivot in real time. Europe’s push for tech sovereignty Staying with AI, there’s fresh friction between platforms, publishers, and regulators in the UK. The Competition and Markets Authority says online publishers will be able to opt out of appearing in Google Search’s AI Overviews. The CMA is also pushing for clearer attribution and prominent links back to original sources when publisher content shows up in AI-generated summaries. The aim is to give publishers more leverage to negotiate content deals—and potentially payments—at a moment when many say AI answers are cutting into referral traffic. Google’s position is essentially: opting out may reduce visibility in AI results, but it won’t hurt traditional search rankings. Either way, this UK trial is shaping up as a test case for how search will coexist with the web ecosystem that feeds it. Google AI Overviews and publishers And in a related debate—this time inside academia—mathematicians have released the Leiden Declaration on Artificial Intelligence and Mathematics, endorsed by the International Mathematical Union. The declaration argues that AI can generate proofs that look convincing but are wrong, increasing the burden on peer review and risking a research record cluttered with errors. It also flags concerns about citations, training data and licensing, and the way proprietary tools and corporate timelines can distort who gets credit for breakthroughs. The underlying point is simple: mathematics depends on verification and openness, and the community is worried that the incentives around AI could undermine both. Math community’s AI warning Now to Europe’s big policy play. The European Commission has unveiled what it’s calling a European Technological Sovereignty Package—meant to strengthen the EU’s ability to build and control foundational technologies like semiconductors, AI, cloud computing, and open source software. It includes two new legislative proposals, plus an open source strategy, and a roadmap for using digital tech and AI in the energy sector. The Commission’s case is that demand for computing capacity is surging, and Europe is still too dependent on external suppliers for core systems that underpin healthcare, energy grids, and public services. In plain terms: Europe wants more choices, fewer choke points, and less risk that geopolitical shocks disrupt essential tech. Microsoft’s Majorana 2 quantum claim On the frontier-tech front, Microsoft is claiming a major step forward in quantum computing with its new Majorana 2 chip. The company says its qubits can stay stable for dramatically longer—around seconds rather than milliseconds—and it frames that as a path toward a commercially useful quantum computer by 2029. The catch is scale: today’s chip has a small number of qubits, while useful machines are expected to need vastly more. And there’s also a credibility question—independent verification is limited because full technical details aren’t widely public, and an accompanying paper hasn’t been peer reviewed. So this is either a meaningful leap—or a claim that still needs to earn trust through outside validation. Largest-ever cosmic magnetic field map Let’s look up—way up. An international team led by CSIRO and the SKA Observatory has released SPICE-RACS, described as the largest map yet of the Universe’s magnetic fields—reportedly five times larger than all previous efforts combined. Built using Australia’s ASKAP radio telescope, the survey tracks how radio signals from distant galaxies get subtly twisted as they pass through magnetic fields. With that, researchers can infer where magnetism is and how strong it is in relative terms. Why it’s interesting isn’t just the sheer scale: the density of this dataset could open better research into how magnetic fields shape galaxy growth, influence how matter moves through space, and affect the Universe’s long-term evolution. It may also sharpen studies closer to home, including interactions involving the Milky Way and the Magellanic Clouds. The data is public, and the results have been accepted for publication in Australia’s main astronomy journal—while future SKA operations are expected to map the cosmic web in even finer detail. GLP-1 drugs and cancer signals In health news, early research presented at the American Society of Clinical Oncology meeting is adding momentum to a provocative question: could GLP-1 drugs—best known for diabetes care and weight loss—also be linked to better outcomes in multiple cancers? Across more than two dozen mostly observational studies, GLP-1 users showed signals like lower risk for certain cancers, less progression and metastasis, and in some datasets, improved survival. One large study of women, for example, associated GLP-1 use with a noticeably lower risk of breast cancer. Researchers suspect the story may go beyond weight loss, potentially involving inflammation and insulin-related pathways, and some findings even hint at better responses alongside immunotherapies. The important caveat: observational data can’t prove cause and effect. The takeaway is that the consistency of these signals is now strong enough that many experts want rigorous randomized trials to find out what’s real—and what’s just correlation. Injectable microrobots for spinal repair Also in medical science, researchers at ETH Zurich report progress on a hard problem: repairing spinal cords where scar tissue and limited natural regrowth block reconnection. Their approach uses injectable microrobots that combine neural progenitor stem cells with nanoparticles designed to respond to external electromagnetic signals. In mouse experiments with severed spinal cords, electrically stimulating the injury area helped nerve cells begin reconnecting within about four weeks, and the animals showed substantial improvements in movement and coordination. The study, published in Nature Materials, is still early-stage—human testing would require careful work on safety, dosing, and the strength and duration of magnetic-field settings. But it’s a compelling example of combining regenerative cells with targeted stimulation in a way that could, eventually, be more scalable than highly invasive procedures. Sterile mosquito proposal in US A very different

    9 min
  6. Breakthrough RAS drug for cancer & Personalized mRNA vaccine for melanoma - News (Jun 3, 2026)

    5d ago

    Breakthrough RAS drug for cancer & Personalized mRNA vaccine for melanoma - News (Jun 3, 2026)

    Please support this podcast by checking out our sponsors: - Consensus: AI for Research. Get a free month - https://get.consensus.app/automated_daily - Effortless AI design for presentations, websites, and more with Gamma - https://try.gamma.app/tad - KrispCall: Agentic Cloud Telephony - https://try.krispcall.com/tad Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily Today's topics: Breakthrough RAS drug for cancer - A major pancreatic cancer trial reports daraxonrasib, a broad RAS inhibitor, nearly doubled median survival—reviving hopes against long-"undruggable" targets like RAS and MYC. Personalized mRNA vaccine for melanoma - Five-year data suggest a personalized mRNA cancer vaccine plus Keytruda reduced melanoma recurrence and improved overall survival, strengthening the case for mRNA in oncology. New immunotherapy booster in lung cancer - A Scottish stage-four lung cancer patient describes meaningful tumor shrinkage in a trial of GRWD5769, a drug aimed at blocking cancer immune-escape and boosting immunotherapy response. Ultrasound wearable pacemaker progress - MIT researchers demonstrated a noninvasive, ultrasound-driven pacing approach using a small chest sticker and engineered heart cells, pointing toward surgery-free rhythm control for arrhythmias. Microsoft Majorana 2 quantum chip claims - Microsoft says its Majorana 2 quantum chip improves qubit stability dramatically, but scientists are asking for peer-reviewed evidence and clearer independent verification. AI worm risks from open models - University of Toronto researchers showcased a proof-of-concept "AI worm" that adapts across devices using open-weight models, raising urgent questions for cybersecurity and infrastructure defense. EU digital sovereignty push on tech - The European Union is preparing a strategy to reduce reliance on US and Asian tech by expanding EU cloud, AI, and semiconductor capacity, citing supply-chain and data-sovereignty concerns. UK rules on Google AI Overviews - The UK CMA will let publishers opt out of Google Search AI Overviews and require clearer attribution, a test case for how generative AI impacts traffic and content payments. Maternal health crisis in CAR camps - In refugee camps near Birao, Central African Republic, funding cuts and conflict are worsening maternal health access, with rising risks from lost midwives, closed services, and limited prenatal care. Pope’s encyclical and AI fairness - Pope Leo XIV’s encyclical calls for human-centered, truth-focused technology, as publishers cite collapsing click-through rates and a growing "scraper economy" exploiting online content. Episode Transcript Breakthrough RAS drug for cancer Let’s start with that cancer breakthrough. A large clinical trial reports that an experimental medicine called daraxonrasib, designed to broadly shut down the RAS family of proteins, nearly doubled median survival for people with a form of advanced pancreatic cancer. Patients on the new drug lived a median of 13.2 months, compared with 6.7 months on standard chemotherapy—results presented at the American Society of Clinical Oncology meeting and published in The New England Journal of Medicine. The bigger story here is historical: RAS has been notoriously hard to target, and past drugs tended to work only for narrow mutations and then hit resistance. Researchers now say this broader RAS approach could unlock combination strategies—and energize efforts against other difficult cancer drivers, including MYC, as well as new attempts to restore the tumor-suppressor p53. Personalized mRNA vaccine for melanoma Staying with oncology, five-year results are strengthening the case for personalized mRNA cancer vaccines—this time in high-risk melanoma. In a study following patients after surgery, the group that received a tailor-made mRNA vaccine plus Keytruda stayed cancer-free at a higher rate than those on Keytruda alone, with overall survival also coming in higher in the combination group. What makes this interesting is the direction of travel: it’s not just treating cancer in the moment, it’s training the immune system to recognize what’s unique about an individual tumor and keep watch for a relapse. Side effects were generally manageable, and a much larger Phase 3 trial is underway to confirm these benefits and potentially support regulatory approval. New immunotherapy booster in lung cancer And another glimpse of what “next-generation” cancer care might look like comes from a personal story out of Scotland. Pat Brogan, who has stage four lung cancer, says an experimental “smart drug” in a clinical trial helped shrink his tumors by almost a third after years of chemotherapy and immunotherapy—and after his disease began progressing again. The drug, known as GRWD5769, is intended to stop cancer cells from slipping past the immune system, effectively making existing immunotherapy more capable of doing its job. It’s one patient’s experience, not a verdict, but it illustrates why researchers are so focused on immune-escape mechanisms: they may offer fresh options when standard treatments run out of room. Ultrasound wearable pacemaker progress From cancer to cardiology now, with a development that sounds almost sci-fi but is rooted in practical aims: MIT engineers and collaborators have built a prototype for a noninvasive “pacemaker” that uses ultrasound delivered from a tiny chest sticker. In lab and animal tests, the system helped correct irregular heart rhythms without surgical implantation. The approach hinges on making heart cells more responsive to ultrasound, so a gentle external signal can help coordinate beating. It’s still early—there are big steps between rats and routine human care—but the headline is simple: a future where pacing could be adjustable, wearable, and potentially surgery-free, lowering barriers for patients who need rhythm support. Microsoft Majorana 2 quantum chip claims Switching to technology, Microsoft is drawing attention with a new quantum chip it calls Majorana 2. The company says this version is about a thousand times more reliable than its previous effort, with qubits staying stable for roughly 20 seconds rather than milliseconds. If true, that kind of stability matters because fragile qubits are one of the main reasons quantum computing has struggled to move from demos to dependable machines. Microsoft is also making an ambitious claim about timing—suggesting commercially useful quantum problems could be in reach by 2029—while acknowledging that scaling would require vastly more qubits than it has today. The caution flag: independent verification is limited so far, and researchers are asking for peer-reviewed evidence and more public detail, especially given the history of controversy around Microsoft’s earlier Majorana-related work. AI worm risks from open models Now to cybersecurity, where researchers at the University of Toronto say they’ve demonstrated a proof-of-concept “AI worm” that can adapt as it spreads—using publicly available, open-weight AI models. Instead of following a rigid script, the worm can probe each machine, exploit known weaknesses, gather credentials, and then adjust its next steps as it moves through a network. One of the most worrying ideas here is economic: if the malware can commandeer infected machines to run its own AI-driven decision-making, the cost of expanding an attack could drop sharply after the initial launch. The team says it worked in a controlled lab and that they removed details that would directly help attackers, but the warning is clear—defenses built for predictable malware may struggle against threats that can improvise. EU digital sovereignty push on tech In Europe, the policy spotlight is on digital independence. The European Union is set to unveil a strategy aimed at reducing reliance on US and Asian technology by bolstering European capacity in semiconductors, cloud computing, and artificial intelligence. EU officials point to a striking dependency: a large share of Europe’s digital products and infrastructure comes from foreign providers, and US companies dominate the cloud market. The plan reportedly includes measures to encourage EU-based data center construction and boost demand for Europe-made chips, along with “sovereignty” criteria in public procurement. The drivers include worries about cross-border data access, supply-chain disruptions, and the risk that political decisions elsewhere could affect essential services at home. UK rules on Google AI Overviews That theme—who benefits from the digital economy, and who gets squeezed—also shows up in the UK, where the Competition and Markets Authority is forcing changes to Google Search’s AI Overviews. UK online publishers will be able to opt out of appearing in AI-generated summaries, and Google will be required to attribute publisher material more clearly with prominent links back to original sources. The goal is to give publishers more leverage to negotiate content deals and potential payments, as many argue that AI answers are cannibalizing referral traffic. Google says opting out may reduce visibility in AI results, but it won’t affect rankings in traditional search listings. This will be trialed in the UK first, and it’s a closely watched test of whether regulators can rebalance power between platforms and creators. Maternal health crisis in CAR camps And in the wider cultural debate over AI, Pope Leo XIV has entered the conversation with his first encyclical, “Magnifica Humanitas,” calling for a truth-centered approach to technology and stronger protection for people who create. While it’s not a policy document, publishers are reading it as moral backing at a moment when they say AI is undermining their economics—both through training on copyrighted work and through search-like AI products that answer questions without sending u

    9 min
  7. RAS breakthrough in pancreatic cancer & Personalized mRNA vaccine for melanoma - News (Jun 2, 2026)

    6d ago

    RAS breakthrough in pancreatic cancer & Personalized mRNA vaccine for melanoma - News (Jun 2, 2026)

    Please support this podcast by checking out our sponsors: - SurveyMonkey, Using AI to surface insights faster and reduce manual analysis time - https://get.surveymonkey.com/tad - Consensus: AI for Research. Get a free month - https://get.consensus.app/automated_daily - Invest Like the Pros with StockMVP - https://www.stock-mvp.com/?via=ron Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily Today's topics: RAS breakthrough in pancreatic cancer - A major clinical trial reports daraxonrasib, a broad RAS inhibitor, nearly doubled median survival in advanced pancreatic cancer—challenging the long-held “undruggable” RAS narrative and boosting combination-therapy hopes. Personalized mRNA vaccine for melanoma - Five-year data suggest a personalized mRNA cancer vaccine plus Keytruda lowers melanoma recurrence risk and improves overall survival, strengthening the case for mRNA, neoantigens, and tailored immunotherapy in high-risk patients. New options for hard-to-treat cancers - Several oncology updates point to fresh approaches for resistant disease: an immune-escape ‘smart drug’ showing early promise, strong responses to injectable amivantamab in recurrent head and neck cancer, and improved surgical outcomes in high-risk prostate cancer. Ultrasound sticker pacemaker research - MIT-led researchers tested a noninvasive pacemaker concept: a small chest sticker delivering ultrasound pulses to regulate heart rhythm, hinting at future surgery-free pacing and closed-loop wearable cardiac care. Maternal health crisis in CAR camps - A report from a refugee camp near Birao describes women giving birth without transport, staff, or supplies as humanitarian funding cuts deepen a maternal mortality emergency in conflict-hit Central African Republic. Ukraine alleges child abductions - President Zelenskyy says Ukraine has evidence Russia is abducting Ukrainian children and training them, escalating allegations already tied to an ICC warrant and intensifying calls for tracking, sanctions, and accountability. Google’s mosquito plan for disease - Google is seeking U.S. approval to release millions of Wolbachia-carrying male mosquitoes in California and Florida to curb Aedes aegypti and reduce dengue and Zika risk, reflecting wider climate-driven vector concerns. Episode Transcript RAS breakthrough in pancreatic cancer In cancer research, one of the most striking updates comes from a large pancreatic cancer trial testing an experimental drug called daraxonrasib. Researchers report that patients with a form of advanced pancreatic cancer lived a median of 13.2 months on the new drug, compared with 6.7 months on standard chemotherapy. That’s a huge deal not just because pancreatic cancer is so aggressive, but because the drug is designed to shut down the RAS family of proteins—targets that scientists have struggled with for decades. The takeaway is simple: if broad RAS inhibition holds up and side effects can be managed, this could reshape how multiple RAS-driven cancers are treated, potentially by pairing broad blockers with mutation-specific drugs to stay ahead of resistance. Personalized mRNA vaccine for melanoma Staying with oncology, there’s also encouraging long-term evidence for personalized mRNA vaccines in melanoma. Five-year results from a clinical study suggest that adding a custom-made mRNA vaccine to the immunotherapy Keytruda helped keep more people cancer-free after surgery. About two-thirds of patients on the combination were still cancer-free at five years, compared with roughly half of those on Keytruda alone, and overall survival was higher as well. What makes this interesting is the direction of travel: cancer care is increasingly about training the immune system with instructions tailored to an individual tumor, rather than using one-size-fits-all treatments. A much larger trial is already underway, and if it confirms the benefit, it could push personalized cancer vaccines closer to routine care. New options for hard-to-treat cancers A few other cancer developments are worth a quick stop because they point to the next wave of options for patients who’ve run out of road with standard therapies. In Scotland, a man with stage four lung cancer says an experimental “smart drug” in a clinical trial helped shrink his tumors by nearly a third after prior chemotherapy and immunotherapy stopped working. Early patient stories don’t replace large datasets, but they do highlight a growing focus on blocking the ways tumors hide from the immune system—an area that could make existing immunotherapies work better, for longer. Ultrasound sticker pacemaker research Another headline: an injectable drug called amivantamab showed unusually strong responses in a study of people with head and neck cancer that had returned or resisted treatment. Researchers reported rapid tumor shrinkage in a notable share of patients, including some complete disappearances. For a population with limited alternatives, even a modest improvement can matter; seeing fast, deep responses is what gets clinicians’ attention and drives bigger, confirmatory trials. Maternal health crisis in CAR camps And in prostate cancer, late-stage trial results suggest that adding the drug Erleada to standard hormone therapy around the time of prostate-removal surgery improved outcomes for men with high-risk disease. The big picture here is timing and intensity: treating aggressively before and after surgery may reduce the odds that microscopic cancer cells survive and come roaring back. Regulators will ultimately decide what this changes in practice, but it’s an important signal in a group where recurrence rates remain stubbornly high. Ukraine alleges child abductions From cancer back to the heart—literally—MIT engineers and collaborators have demonstrated a research prototype that hints at a future without implanted pacemakers for some patients. Their concept uses a small chest sticker to deliver ultrasound pulses that can regulate heartbeats. In animal experiments, the system quickly corrected abnormal rhythms, but it relies on a key step: making heart cells more responsive to ultrasound through a gene-therapy-like approach. That means this is not something heading to clinics tomorrow. Still, it’s notable because it imagines pacing as something adjustable, wearable, and potentially surgery-free—a very different model from today’s implanted hardware. Google’s mosquito plan for disease Now to a sobering public health and humanitarian update from the Central African Republic. Reporting from a refugee camp near Birao describes a Sudanese woman delivering her baby on the street after becoming sick and unable to afford transport or access a midwife. The wider issue is that conflict and displacement magnify pregnancy risks, and sub-Saharan Africa accounts for the majority of maternal deaths worldwide. Aid groups say recent funding cuts have forced closures of safe spaces, reduced reproductive health supplies, and eliminated key staff positions—exactly the supports that prevent emergencies from turning fatal. When prenatal care is missed and clinics are overwhelmed, complications are caught late, and tragedies become more common than they should be. Story 8 In global affairs, Ukraine’s President Volodymyr Zelenskyy told CBS News that Ukraine has evidence Russia is abducting Ukrainian children and training them to fight against Ukrainians—an allegation that, if proven, would sharpen already serious accusations into an even darker category. The claim goes beyond earlier reports about children being sent to camps for reeducation. Zelenskyy also said children are being treated as bargaining chips in exchanges, which would violate basic protections for civilians under international law. The International Criminal Court already issued an arrest warrant for Vladimir Putin in 2023 related to alleged unlawful deportations of children, while Russia maintains it is providing humanitarian care. Ukraine says it has documented at least 20,000 abducted children and is calling for more international help to locate and return them. Story 9 Finally, a public health story with a climate angle: Google is seeking U.S. approval to release up to tens of millions of male mosquitoes in parts of California and Florida. The idea is to reduce populations of Aedes aegypti, an invasive species linked to illnesses like dengue and Zika. These released males carry a naturally occurring bacterium called Wolbachia that prevents viable offspring when they mate with wild females, shrinking the next generations without relying on broad pesticide spraying. It’s one more sign that as warming temperatures and global travel expand mosquito habitat and lengthen transmission seasons, communities are looking for new tools that are targeted, trackable, and less chemically intensive. Subscribe to edition specific feeds: - Space news * Apple Podcast English * Spotify English * RSS English Spanish French - Top news * Apple Podcast English Spanish French * Spotify English Spanish French * RSS English Spanish French - Tech news * Apple Podcast English Spanish French * Spotify English Spanish Spanish * RSS English Spanish French - Hacker news * Apple Podcast English Spanish French * Spotify English Spanish French * RSS English Spanish French - AI news * Apple Podcast English Spanish French * Spotify English Spanish French * RSS English Spanish French Visit our website at https://theautomateddaily.com/ Send feedback to feedback@theautomateddaily.com Youtube LinkedIn X (Twitter)

    7 min
  8. Brain cells playing Doom & Breakthrough injections for cancer - News (Jun 1, 2026)

    Jun 1

    Brain cells playing Doom & Breakthrough injections for cancer - News (Jun 1, 2026)

    Please support this podcast by checking out our sponsors: - Effortless AI design for presentations, websites, and more with Gamma - https://try.gamma.app/tad - SurveyMonkey, Using AI to surface insights faster and reduce manual analysis time - https://get.surveymonkey.com/tad - Discover the Future of AI Audio with ElevenLabs - https://try.elevenlabs.io/tad Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily Today's topics: Brain cells playing Doom - Researchers in Melbourne trained lab-grown human neurons on a chip to play Doom, highlighting adaptive learning and potential energy-efficient computing beyond today’s AI. Breakthrough injections for cancer - A triple-action cancer injection, amivantamab, showed unusually strong responses in hard-to-treat head and neck cancer, while Johnson & Johnson reported improved outcomes for high-risk localized prostate cancer around surgery. AI chip boom and bottlenecks - Micron and SK Hynix topping $1 trillion market caps spotlights high-bandwidth memory as a key AI data-center bottleneck, while Nvidia says “AI factories” and AI agents are reshaping investment and jobs. US-Iran strikes and Hormuz - The US said it struck Iranian radar and drone command sites after a drone incident, Iran signaled retaliation, and the Strait of Hormuz remains effectively blocked—raising global oil and LNG supply concerns. Ukraine strikes, children allegations - Ukraine hit Russian oil facilities with long-range drones as Russia warned of broader strikes; Zelenskyy also alleged child abductions and forced training—adding pressure for investigations and sanctions. AI helping artists create - Singer-songwriter Samuel Smith used AI music tools as an assistive creative bridge after Parkinson’s limited his guitar playing, underscoring AI’s growing role in preserving artistic intent. Episode Transcript Brain cells playing Doom Let’s start with the story that sounds like science fiction. Researchers at Melbourne-based Cortical Labs say they’ve trained lab-grown human neurons—living on a silicon chip—to play the classic shooter game Doom. The neurons didn’t start out skilled. Early on, they behaved like a clueless beginner: bumping into walls, firing randomly, and getting nowhere fast. But with continued training, the cultures began to respond more purposefully, increasingly targeting enemies and adapting in real time. This isn’t about turning brain cells into gamers. The bigger idea is that biology learns with very low energy use compared with today’s power-hungry computing. The team says platforms like this could eventually help with drug testing and disease modeling, even if it’s still early and the neuron cultures don’t last long. Breakthrough injections for cancer Now to medicine, where two cancer updates are drawing attention ahead of the American Society of Clinical Oncology meeting. First: doctors reported what they called “unprecedented” results from an international trial of amivantamab, a triple-action injection for people with recurrent or metastatic head and neck cancer that had stopped responding to standard chemotherapy and immunotherapy. In a study spanning 11 countries and 102 patients, tumors shrank or disappeared in 43 people. Fifteen patients saw their tumors vanish entirely, and some changes showed up within weeks. What makes this especially notable is the setting: once head and neck cancers reach this stage—often HPV-negative—the options can be limited and outcomes are typically poor. The treatment is delivered as an under-the-skin jab every three weeks, potentially simpler than regular intravenous infusions. Side effects were mostly mild to moderate, and fewer than one in ten people stopped treatment. Median overall survival after starting therapy was reported at 12.5 months—an important signal in a group where the bar is painfully low. AI chip boom and bottlenecks The second cancer story comes from Johnson & Johnson in high-risk prostate cancer—earlier-stage disease, but still one that frequently comes back after today’s standard treatment. In a late-stage trial, adding the drug Erleada to standard testosterone-suppressing hormone therapy around the time of prostate-removal surgery improved outcomes in men with high-risk localized or locally advanced cancer. Patients on the combination were far more likely to have minimal to no detectable cancer at surgery, and the company reported meaningful reductions in the risk of progression or death. If these results hold up and regulators agree, it could change the treatment playbook for a large group of patients—especially since a significant share of prostate cancer diagnoses in the US fall into the high-risk category. US-Iran strikes and Hormuz Shifting to technology and markets: memory chips—long treated as a commodity corner of the semiconductor world—are now being priced like strategic infrastructure for AI. Micron and South Korea’s SK Hynix have both climbed to market values above one trillion dollars. The driver is high-bandwidth memory, or HBM, which has become a choke point for AI data centers. In plain terms: AI systems can be limited not only by how fast they compute, but by how quickly they can access the right data. When that kind of memory is scarce, the suppliers gain leverage—through demand, through pricing power, and through longer-term orders that look less “boom and bust” than past chip cycles. The broader takeaway is that investors are increasingly treating memory as essential to AI growth, not just a cyclical bet that rises and falls with gadget demand. Ukraine strikes, children allegations And speaking of AI hardware, Nvidia’s CEO Jensen Huang used GTC Taipei to argue that AI has moved from experiments to profit engines—and even a contributor to GDP growth. Huang’s core message was that companies are building “AI factories” because the output of AI—what he framed as a flood of usable work products—can be monetized. He also pushed back on the idea that AI automatically means fewer jobs, saying AI-assisted coding can increase productivity and, in some cases, lead to hiring more engineers. He predicted that “AI agents” will become a kind of digital labor force, eventually numbering in the billions. Whether you buy the timeline or not, the direction is clear: companies are betting that software that can plan, remember, and act will be a major new layer of the economy. AI helping artists create Now to the Middle East, where tensions around the Strait of Hormuz are escalating again—with implications that extend well beyond the region. The US says it carried out weekend “self-defence” strikes on Iranian radar and drone command-and-control sites near Iran’s southern coast and on Qeshm Island, following what Washington described as aggressive Iranian actions, including the downing of a US drone over international waters. Iran’s Revolutionary Guard said it responded by targeting an air base in Kuwait used by US forces. Kuwait reported hostile missiles and drones, and air-raid sirens reportedly sounded nationwide. US Central Command said two Iranian ballistic missiles aimed at US forces in Kuwait were intercepted, and that no American personnel were hurt. This is the third major escalation in a week, and the Strait of Hormuz remains effectively blocked—a critical problem for global oil and LNG shipments. Ceasefire-extension talks appear to be stalling, with reports that proposed terms and demands are shifting. The key risk here is miscalculation: even limited tit-for-tat actions can rattle energy markets when the shipping lane is already constrained. Story 7 Turning to Ukraine: overnight drone strikes set fires at Russian oil facilities, according to Russian officials, including reported damage in Taganrog in the Rostov region and a separate fire in Armavir in the Krasnodar region. President Volodymyr Zelenskyy highlighted that Armavir is roughly 500 kilometers from Ukraine’s border—an underscore of Ukraine’s growing long-range reach. The strategy is straightforward: oil infrastructure helps fund Russia’s war effort, and disrupting it can raise costs and create logistical headaches. Russia, meanwhile, continues long-range attacks on Ukrainian cities and infrastructure, and Kyiv is bracing for what Moscow has called broader “systemic strikes.” Zelenskyy is again urging the US for more Patriot air defenses. Tensions also rose after a Russian drone strike injured two people in Romania, a NATO member—fueling concern about spillover. And in another reminder of the risks, Russia’s Rosatom said a Ukrainian drone hit the Russian-controlled Zaporizhzhia nuclear power plant, causing minor damage but no reported harm to critical equipment. The IAEA has warned repeatedly: even small incidents at a nuclear site carry outsized danger. Story 8 One more Ukraine-related development is drawing sharp scrutiny. Zelenskyy told CBS News that Ukraine has evidence Russia is abducting Ukrainian children and training them to fight against Ukrainians—an allegation that, if proven, would intensify war-crimes concerns. The claim goes beyond earlier reporting about children being sent to camps for reeducation or “Russification.” Zelenskyy also said children are being treated as bargaining chips, offered in exchanges for captured soldiers—something he argues is plainly illegal under international humanitarian law. Ukraine says it has documented at least 20,000 abducted children. Russia has framed its actions as humanitarian care for war orphans, but the International Criminal Court issued an arrest warrant for Vladimir Putin in 2023 over alleged unlawful deportation of children. The next question is whether international bodies and governments can verify new evidence quickly—and what pressure follows. Story 9 Finally, a quieter story about AI’s role in everyday life—this time in music. Lond

    9 min
See All (100)

About

Welcome to 'The Automated Daily - Top News Edition', your ultimate source for a streamlined and insightful daily news experience.

Information

More From The Automated Daily